Search Login Register

verteporfin (Visudyne) Summary

Description: C41H42N4O8, MW 718.794; used in PHOTOCHEMOTHERAPY to treat wet type MACULAR DEGENERATION

Also Known As: Visudyne; 18-ethenyl-4,4a-dihydro-3,4-bis(methoxycarbonyl)-4a,8,14,19-tetramethyl-23H,25H-benzo(b)porphine-9,13-dipropanoic acid monomethyl ester; BPD verteporfin; BPD-MA; Novartis Ophthalmics brand of verteporfin Show All >>

Networked: 718 relevant articles (105 outcomes, 146 trials/studies) for this Drug

Key Diseases for which verteporfin is Relevant

  1. Choroidal Neovascularization : 36 outcomes 57 studies in 280 results
  2. Macular Degeneration (Age-Related Maculopathy) : 30 outcomes 68 studies in 287 results
  3. Central Serous Chorioretinopathy : 17 outcomes 7 studies in 61 results
  4. Neoplasms (Cancer) : 7 outcomes 19 studies in 78 results
  5. Hemangioma (Angioma) : 7 outcomes 1 study in 19 results
Show All >>

Drugs Related to verteporfin

  1. 1-phenyl-3,3-dimethyltriazene (PDT)
  2. verteporfin (Visudyne)
  3. ranibizumab (Lucentis)
  4. Triamcinolone Acetonide (Azmacort)
  5. Retinaldehyde (Retinal)
  6. Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
  7. bevacizumab
  8. Fluorescein (Funduscein)
  9. Liposomes (Liposome)
  10. Indocyanine Green (Cardio-Green)
Show All >>

Therapies Related to verteporfin

  1. Photochemotherapy (Photodynamic Therapy)
  2. Intravitreal Injections
  3. Lasers (Laser)
  4. Induced Hyperthermia (Thermotherapy)
  5. Phototherapy (Light Therapy)
Show All >>

CureHunter Inc. provides medical information and specifically does NOT provide medical advice.
© Copyright 2003-2016 CureHunter Inc., MeSH copyright NLM, Journal Articles copyright original owners.